---
title: "InfuSystem Holdings, Inc 2Q 2026: Revenue $36.93M, EPS $0.15— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294861600.md"
description: "InfuSystem Holdings reported Q2 2026 revenue of $36.93M (+2.6% YoY) and diluted EPS of $0.15 (+25%). Patient Services revenue rose 15%, driven by Oncology and Wound Care demand, while Device Solutions declined due to contract restructuring despite improved margins. The company launched new ERP systems, expanded its payer network, and acquired the Apollo asset to enhance distribution capabilities."
datetime: "2026-08-04T19:41:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294861600.md)
  - [en](https://longbridge.com/en/news/294861600.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294861600.md)
generator: "portal-rs"
---

# InfuSystem Holdings, Inc 2Q 2026: Revenue $36.93M, EPS $0.15— 10-Q Summary

InfuSystem Holdings, Inc reported second-quarter 2026 results with revenue of $36.93M and diluted EPS of $0.15, reflecting modest top-line growth and higher profitability versus the year‑ago quarter.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$36.93M

$36M

2.6%

Net income²

$3.23M

$2.6M

24.3%

Diluted EPS³

$0.15

$0.12

25%

*¹ Reported as “Net revenues”. ² Reported as “Net income”. ³ Reported as “Diluted income per share”.*

**Business Highlights**

-   Patient Services revenue rose 15% year over year in the quarter, driven by Oncology and Wound Care demand.
-   Wound Care expansion, including PCD/ACW product launches, contributed to an improved channel and product mix.
-   Device Solutions revenue declined due to a GE contract restructuring and a prior rental buyout, but gross margins improved from restructuring, procurement and productivity actions.
-   ERP went live March 1, 2026; the company is managing tapering post‑go‑live costs and ongoing system stabilization and enhancements.
-   Commercial progress included an expanded payer network, new supplier partnerships and the Apollo asset acquisition to strengthen distribution and wound care fulfillment.

Original SEC Filing: InfuSystem Holdings, Inc \[ INFU \] - 10-Q - Aug. 04, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [INFU.US](https://longbridge.com/en/quote/INFU.US.md)
- [GE.US](https://longbridge.com/en/quote/GE.US.md)
- [APO.US](https://longbridge.com/en/quote/APO.US.md)
- [APO-A.US](https://longbridge.com/en/quote/APO-A.US.md)
- [APOS.US](https://longbridge.com/en/quote/APOS.US.md)

## Related News & Research

- [INFU: Record revenue and margin gains fueled by Oncology and wound care growth, with positive outlook](https://longbridge.com/en/news/294840749.md)
- [Clorox (CLX) And The ERP Case For A Modestly Undervalued Stock](https://longbridge.com/en/news/297786975.md)
- [13:07 ETWestern Computer Achieves the 2026/2027 Microsoft AI Business Solutions Inner Circle Award](https://longbridge.com/en/news/298062354.md)
- [Is Solventum (SOLV) Fairly Valued On Raised 2026 Guidance Despite Debt And Cost Headwinds?](https://longbridge.com/en/news/297884468.md)
- [10:54 ET/C O R R E C T I O N -- VirtuAlly/](https://longbridge.com/en/news/297669914.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**